Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria
NCT01642017 · Institut Claudius Regaud · PHASE1 · terminated · last registry update 2026-04-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow recruitment rate” | – | Registry record, Institut Claudius Regaud |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Also stopped (terminated): Gossamer Bio USA, Inc., GB002 (seralutinib) (NCT04816604)
- 2026-10-20Phase 3 first posted: Sun Yat-sen University, Benmelstobart + Anlotinib (NCT07881900)
- 2026-10-05Also stopped (suspended): M.D. Anderson Cancer Center, Cyclophosphamide + Axatilimab (SNDX-6352) (NCT06959537)
- 2026-10-05Results posted on the registry: Incyte Biosciences Japan GK, INCA034176 (NCT06263478)
- 2026-09-03Also stopped (withdrawn): Mayo Clinic, Axatilimab + Cyclophosphamide (NCT07349771)
- 2026-08-31Results posted on the registry: University of Texas Southwestern Medical Center, a drug against CSF1R (NCT02956798)
- 2026-08-25Also stopped (terminated): Association of Urologic Oncology (AUO), Sunitinib + Placebo (NCT01216371)
- 2026-07-09Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Paclitaxel or Docetaxel and Carboplatin or Cisplatin (NCT02009449)
- 2026-07-09Also stopped (terminated): Washington University School of Medicine, Paclitaxel + Carboplatin (NCT04331067)
- 2026-04-08Results posted on the registry: National Cancer Institute (NCI), Olaparib + Pazopanib (NCT05432791)
- 2026-03-19Also stopped (suspended): GB002, Inc., Placebo + Seralutinib (NCT07181382)
- 2026-03-18Phase 3 first posted: PETHEMA Foundation, Azacitidine + Venetoclax (NCT07478991)
- 2026-02-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Gilteritinib + Venetoclax (NCT07425808)
- 2025-10-21Phase 3 first posted: GlaxoSmithKline, IDRX-42 + Sunitinib (NCT07218926)
- 2025-10-16Results posted on the registry: NYU Langone Health, Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks + Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks (NCT04050462)
- 2025-10-16Also stopped (terminated): NYU Langone Health, Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks + Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks (NCT04050462)
- 2025-09-18Phase 3 first posted: GB002, Inc., Placebo + Seralutinib (NCT07181382)
- 2025-09-10Phase 3 first posted: Peking University Cancer Hospital & Institute, Vorolanib Tablets+Everolimus + Sunitinib (NCT07165418)
- 2025-08-06Results posted on the registry: Hitendra Patel, Gemcitabine + Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] (NCT03697564)
- 2025-05-02Results posted on the registry: M.D. Anderson Cancer Center, Pazopanib Hydrochloride (NCT01436227)
- 2025-04-30Also stopped (terminated): University of Washington, Sirolimus Albumin-bound Nanoparticles + Pazopanib hydrochloride (NCT03660930)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision